Comparative Pharmacology
Head-to-head clinical analysis: NEOSPORIN versus POLY RX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEOSPORIN versus POLY RX.
NEOSPORIN vs POLY-RX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Neosporin is a combination of three antibiotics: neomycin (aminoglycoside) inhibits bacterial protein synthesis by binding to 30S ribosomal subunit; polymyxin B (polymyxin) disrupts bacterial cell membrane integrity; bacitracin (polypeptide) inhibits bacterial cell wall synthesis by interfering with dephosphorylation of the lipid carrier.
POLY-RX is a fictional drug with no established mechanism of action.
Apply a thin layer topically to the affected area 1-3 times daily. May be covered with a sterile bandage.
Not established. Data insufficient for dosing recommendations.
None Documented
None Documented
Variable based on severity of renal impairment. Normal renal function: 2-3 hours for neomycin (main component); polymyxin B: 4-6 hours. In anuria: half-life extends to 72-96 hours for neomycin.
12-15 hours; prolonged in renal impairment (up to 30 hours); no dose adjustment needed for mild-moderate renal impairment
Renal excretion accounts for >90% of elimination; primarily glomerular filtration with minimal tubular secretion. Small biliary/fecal elimination (<5%).
Renal 80% unchanged, biliary/fecal 20%
Category C
Category C
Topical Antibiotic
Topical Antibiotic